Xencor Posts $39.4 Million Quarterly Profit As Revenue Hits $116.5 Million, Up From $21.0 Million

Royalties from Alexion and Incyte and an Astellas milestone drove the swing from a year-earlier loss; nine-month results are still a loss.

Share
Xencor Posts $39.4 Million Quarterly Profit As Revenue Hits $116.5 Million, Up From $21.0 Million

Xencor, a clinical-stage biotech that develops engineered antibodies for cancer and autoimmune disease, earned $39.4 million in the third quarter, or $0.50 per diluted share, against a $6.0 million loss a year earlier. Revenue reached $116.5 million, up from $21.0 million, the company reported Wednesday.

Royalties and a milestone carry the quarter

Xencor said third-quarter revenue came mainly from royalties paid by Alexion and Incyte and a milestone payment from Astellas. The Astellas payment, $25.0 million, was triggered when the first patient was dosed in a Phase 3 trial of ASP2138 in gastric and gastroesophageal junction cancers.

Spending rose. Research and development expenses were $84.3 million, versus $54.4 million a year earlier, on higher external and internal development costs. General and administrative costs fell to $9.4 million from $14.2 million, which the company attributed mainly to a non-recurring recovery of legal expenses.

Other income, net, was $16.4 million, down from $41.5 million, because of lower unrealized gains on an equity security. For the first nine months, Xencor still lost $111.2 million.

Cash and the Alexion settlement

Cash, cash equivalents and marketable debt securities totaled $555.7 million at September 30, compared with $610.8 million at the end of 2025. Xencor expects to finish 2026 with $480 million to $500 million, enough to fund operations into 2029.

Under its settlement with Alexion, Xencor received $52.5 million in August and is due a final $52.5 million in the third quarter of 2027. The company also took in $66.9 million from sales of an equity security.

XmAb819 and the FDA

Xencor, which licenses its XmAb antibody technology to partners and runs early-stage trials of its own drugs, is pushing its kidney cancer drug XmAb819 toward a registration path. In the first half of 2027 it plans to talk with the FDA about a possible accelerated approval route for patients with advanced clear cell renal cell carcinoma who have exhausted standard treatments.

At the 400 mcg/kg intravenous dose, five of 11 evaluable patients had confirmed partial responses, a 45.5% confirmed response rate by investigator assessment as of an October 1 data cut. Xencor chose that dose as its proposed Phase 3 dose and plans a global Phase 3 against tivozanib by the end of 2027, subject to regulatory feedback.

CEO Bassil Dahiyat said the company expects XmAb819 to be the third XmAb 2+1 bispecific antibody to enter a potential registration-enabling study by the end of 2027, after xaluritamig and ASP2138.

Xencor will present early plamotamab data in rheumatoid arthritis at the ACR Convergence conference on Monday, November 9, in a poster session from 10:30 a.m. to 12:30 p.m. ET.

Sources

More on Xencor

All Xencor (XNCR) coverage →